Chagas disease in immunocompromised patients

Area of Science:

• Infectious Diseases
• Immunology
• Tropical Medicine

Background:

• Chagas disease, caused by Trypanosoma cruzi, remains a significant public health concern in the Americas.
• Immunocompromised individuals are at high risk for Trypanosoma cruzi reactivation, which can be fatal.
• Current evidence-based practices for managing Trypanosoma cruzi reactivation vary based on the type of immunosuppression.

Purpose of the Study:

• To review current epidemiology, testing, and management strategies for Trypanosoma cruzi infection in immunocompromised populations.
• To highlight the challenges and specific considerations for managing Chagas disease in immunocompromised hosts.
• To provide healthcare professionals and researchers with updated recommendations.

Main Methods:

• Literature review of available data on Chagas disease epidemiology.
• Synthesis of information on screening and diagnostic approaches for Trypanosoma cruzi infection.
• Analysis of treatment and monitoring practices for immunocompromised patients.

Main Results:

• Immunocompromised patients with Chagas disease face a substantial risk of Trypanosoma cruzi reactivation, irrespective of prior treatment.
• Management strategies for preventing and treating reactivation differ significantly depending on the underlying cause of immunosuppression.
• Populations reviewed include individuals with HIV and transplant recipients (solid organ and hematopoietic stem cell).

Conclusions:

• Effective screening, diagnosis, and monitoring are essential for managing Trypanosoma cruzi infection in immunocompromised patients.
• Proactive management tailored to the type of immunosuppression is critical to prevent potentially lethal reactivation.
• Further research and standardized guidelines are needed to optimize care for this vulnerable patient group.